Phathom Pharmaceuticals(US:PHAT) Globenewswireยท2025-08-07 10:59Core Insights - Phathom Pharmaceuticals reported significant revenue growth in Q2 2025, with net revenues of $39.5 million, up from $7.3 million in Q2 2024, driven by the commercial success of VOQUEZNA products [5][6][11] - The company aims to achieve profitability by 2026, supported by a refined commercial strategy focusing on high-value prescribers and strong prescription trends [2][6][11] Business Highlights - Over 580,000 VOQUEZNA prescriptions have been filled to date, reflecting a 49% increase since the last earnings report [6][7] - Approximately 173,000 VOQUEZNA prescriptions were filled in Q2 2025, representing a 36% sequential growth from Q1 2025 [7] - The prescriber base has expanded, with over 29,300 unique healthcare providers writing prescriptions, a 24% increase since the last quarterly update [7] Financial Performance - R&D expenses for Q2 2025 were $9.1 million, an increase from $7.4 million in Q2 2024, primarily due to one-time restructuring charges [11] - SG&A expenses rose to $85.3 million in Q2 2025 from $75.9 million in Q2 2024, driven by higher personnel-related costs [11] - The net loss for Q2 2025 was $75.8 million, compared to $91.4 million in Q2 2024, with a non-GAAP adjusted net loss of $56.5 million [11][19] Market Position and Strategy - The FDA granted 10-year New Chemical Entity exclusivity for VOQUEZNA, extending market protection until May 2032, which is expected to delay generic competition until at least 2033 [7] - The company has shifted its sales strategy to prioritize gastroenterologists over primary care physicians to enhance prescriber engagement [7] Future Outlook - Phathom expects full-year 2025 revenue to be between $165 million and $175 million, based on strong prescription trends and a refined commercial strategy [6][11] - The company anticipates non-GAAP operating expenses to decrease to less than $60 million in Q3 2025 and less than $55 million in Q4 2025 [11]